Antiparkinson Agents

Known as: antiparkinsonian drugs, ANTI-PARKINSON DRUGS, Antiparkinson Drugs 
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or… (More)
National Institutes of Health

Related topics

Related topics

47 relations

Narrower (38)

24 HR Rotigotine 0.0417 MG/HR Transdermal System24 HR Rotigotine 0.25 MG/HR Transdermal SystemApomorphineBenztropine
(More)

Broader (1)

Central Nervous System Depressants
Cholinergic AntagonistsDopamine AgonistsIn BloodParasympatholytics
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
BACKGROUND Depression is common in patients with Parkinson's disease, but evidence on the efficacy of antidepressants in this… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
BACKGROUND Because of the debate about whether second-generation antipsychotic drugs are better than first-generation… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Dopamine agonists and the risk of cardiac-valve regurgitation.
BACKGROUND Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior.
Two parkinsonian patients who experienced transient hypomanic states when the subthalamic nucleus (STN) was stimulated during… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.
The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
BACKGROUND The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE To compare… (More)
Is this relevant?
Review
2003
Review
2003
The diagnosis of Parkinson's disease
The correct diagnosis of Parkinson's disease is important for prognostic and therapeutic reasons and is essential for clinical… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor…
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
In an attempt to define clinically relevant models of akinesia and dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, we… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They… (More)
  • table 1
  • table 3
  • table 5
  • table 6
  • figure 1
Is this relevant?